ADXS - Ayala Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-1.713M

Cash

7.079M

Avg Qtr Burn

-8.201M

Short % of Float

3.70%

Insider Ownership

0.02%

Institutional Own.

16.65%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AL102 Details Benign tumor, Genetic disorder, Achromatopsia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL101 Details Carcinoma , Salivary gland carcinoma , Salivary gland, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADXS- 504 Details Cancer, Prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL101 Details Leukemia, Acute lymphoblastic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL101 Details Breast cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.